The US Food and Drug Administration (FDA) issued a warning about cybersecurity risks affecting Medtronic insulin pumps. According to the warning, the vulnerabilities enable unauthorised persons to connect wirelessly to the pump and to alter the pump's settings, leading to changes in blood sugar levels and possibly diabetic ketoacidosis. The company recalled the faulty pumps and provided alternative pumps to patients. So far, the FDA has not received any reports of patient harm related to the potential cybersecurity risks.